A report highlights the acceleration of cell and gene therapy approvals worldwide
James Strachan |
The International Society of Cell and Gene therapy (ISCT) has published a snapshot of advanced therapeutic approvals throughout the world (1). ISCT intends the report to be a “living document” – periodically updated and linked to a dedicated section of the ISCT website. Products authorized from 2015 to September 2018 represented 45 percent of all cell, tissue and gene therapy approvals worldwide – highlighting the growing number of marketing authorizations granted by regulators. The US had the greatest number of approved cell, tissue and gene therapies, with 16 (eight products included in this number, however, are based on cord blood hematopoietic progenitors for unrelated donor hematopoietic progenitor cell transplantation; similar products are available in most countries as cell transplants and not as marketed products).
“The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized cell and gene therapies (CGT) as a way to increase communication around the approved therapeutic approaches charged with heightened expectations,” said the authors of the report. “This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization.” Our infographic provides an overview of the key facts and figures.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login as a Guest or via Social Media
- N Cuende et al., “Cell, tissue and gene products with marketing authorization in 2018 worldwide,” Cytotherapy, 20, 1401 1413 (2018). PMID: 30366616.